AU2012301810B2 - FAP-activated proteasome inhibitors for treating solid tumors - Google Patents

FAP-activated proteasome inhibitors for treating solid tumors Download PDF

Info

Publication number
AU2012301810B2
AU2012301810B2 AU2012301810A AU2012301810A AU2012301810B2 AU 2012301810 B2 AU2012301810 B2 AU 2012301810B2 AU 2012301810 A AU2012301810 A AU 2012301810A AU 2012301810 A AU2012301810 A AU 2012301810A AU 2012301810 B2 AU2012301810 B2 AU 2012301810B2
Authority
AU
Australia
Prior art keywords
fap
alkyl
group
ari
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012301810A
Other languages
English (en)
Other versions
AU2012301810A1 (en
Inventor
William W. Bachovchin
Hung-Sen Lai
Sarah E. Poplawski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of AU2012301810A1 publication Critical patent/AU2012301810A1/en
Application granted granted Critical
Publication of AU2012301810B2 publication Critical patent/AU2012301810B2/en
Priority to AU2017204121A priority Critical patent/AU2017204121A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
AU2012301810A 2011-08-30 2012-08-30 FAP-activated proteasome inhibitors for treating solid tumors Active AU2012301810B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204121A AU2017204121A1 (en) 2011-08-30 2017-06-19 FAP-activated proteasome inhibitors for treating solid tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528824P 2011-08-30 2011-08-30
US61/528,824 2011-08-30
PCT/US2012/053140 WO2013033396A2 (en) 2011-08-30 2012-08-30 Fap-activated proteasome inhibitors for treating solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204121A Division AU2017204121A1 (en) 2011-08-30 2017-06-19 FAP-activated proteasome inhibitors for treating solid tumors

Publications (2)

Publication Number Publication Date
AU2012301810A1 AU2012301810A1 (en) 2014-04-10
AU2012301810B2 true AU2012301810B2 (en) 2017-06-01

Family

ID=47757170

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012301810A Active AU2012301810B2 (en) 2011-08-30 2012-08-30 FAP-activated proteasome inhibitors for treating solid tumors
AU2017204121A Abandoned AU2017204121A1 (en) 2011-08-30 2017-06-19 FAP-activated proteasome inhibitors for treating solid tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204121A Abandoned AU2017204121A1 (en) 2011-08-30 2017-06-19 FAP-activated proteasome inhibitors for treating solid tumors

Country Status (14)

Country Link
US (6) US9597410B2 (enExample)
EP (2) EP2753334B1 (enExample)
JP (2) JP6207509B2 (enExample)
CN (2) CN108383893A (enExample)
AU (2) AU2012301810B2 (enExample)
CA (1) CA2846852C (enExample)
DK (1) DK2753334T3 (enExample)
ES (1) ES2929179T3 (enExample)
HR (1) HRP20221320T1 (enExample)
HU (1) HUE060305T2 (enExample)
PL (1) PL2753334T3 (enExample)
PT (1) PT2753334T (enExample)
SI (1) SI2753334T1 (enExample)
WO (1) WO2013033396A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383893A (zh) 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
RU2015123982A (ru) * 2012-12-03 2017-01-13 Ф. Хоффманн-Ля Рош Аг Соединения замещенных триазола и имидазола
EP3008212A4 (en) * 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
HUE063194T2 (hu) * 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
WO2015192124A1 (en) * 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
KR102462240B1 (ko) 2014-07-14 2022-11-03 센트랙스 인터내셔널, 아이엔씨. 효소 억제를 위한 에폭시케톤 화합물
CN104231047B (zh) * 2014-08-22 2017-06-16 亚飞（上海）生物医药科技有限公司 水溶性靶向激活的紫杉醇衍生物及其制备和用途
AU2015306574B2 (en) * 2014-08-22 2020-07-23 Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof
WO2016210054A1 (en) * 2015-06-23 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Novel rhodol fluorophores for near-infrared imaging
CN106588965A (zh) 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN105938123B (zh) * 2015-12-18 2018-09-14 重庆两江药物研发中心有限公司 一种卡非佐米中间体中杂质的检测方法
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
ES2971784T3 (es) 2016-06-21 2024-06-07 Orion Ophthalmology LLC Derivados heterocíclicos de prolinamida
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
ES2988845T3 (es) 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Procedimientos predictivos y diagnósticos para cáncer de próstata
EP3606939A4 (en) * 2017-04-04 2021-01-20 F. Hoffmann-La Roche AG SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND THEIR METHODS OF USE
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR102005030B1 (ko) * 2017-10-31 2019-07-29 충북대학교 산학협력단 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
CN108191957B (zh) * 2017-12-30 2021-05-04 浙江大学 三肽大环衍生物及其制备方法和应用
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
AU2019219057B2 (en) * 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor
MX2021001089A (es) * 2018-08-02 2021-05-12 Chia Tai Tianqing Pharmaceutical Group Co Ltd Borato de derivado de azetidina.
WO2020033437A1 (en) * 2018-08-06 2020-02-13 University Of Kentucky Research Foundation Proteasome inhibitors
GB201820320D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
EP4041747A4 (en) * 2019-10-11 2023-10-18 Mayo Foundation for Medical Education and Research PROTEASOME HIBITORS
CN111235221B (zh) * 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法
CZ309380B6 (cs) * 2020-03-30 2022-10-26 Ústav organické chemie a biochemie AV ČR v. v. i Sloučeniny pro inhibici fibroblastového aktivačního proteinu
CN115968411A (zh) * 2020-06-17 2023-04-14 犹他大学研究基金会 基于生物标记的用于蛋白酶体抑制剂治疗的患者选择
EP4262878A1 (en) * 2020-12-17 2023-10-25 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
IL303655A (en) 2020-12-17 2023-08-01 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2024140736A1 (zh) * 2022-12-27 2024-07-04 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途
WO2025159301A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 섬유아세포 활성화 단백질에 의해 활성화되는 프로드러그 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089312A1 (en) * 2002-04-30 2006-04-27 Bachovchin William W Protease inhibitors
WO2008116054A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2009006473A2 (en) * 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
EP0760059B1 (en) 1994-03-11 2006-05-31 Wilson Greatbatch Ltd. Low power electromagnetic pump
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
CN1163594C (zh) 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
DE04029691T1 (de) 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
AU770319C (en) 1998-05-04 2004-11-25 Point Therapeutics, Inc. Hematopoietic stimulation
JP2002517401A (ja) 1998-06-05 2002-06-18 ポイント セラピューティクス， インコーポレイテッド 環状ボロプロリン化合物
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6285178B1 (en) 1999-02-11 2001-09-04 Battelle Memorial Institute Power supply
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU2002357767C1 (en) 2001-11-26 2009-03-19 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
JP2005511636A (ja) 2001-11-26 2005-04-28 トラスティーズ オブ タフツ カレッジ 自己免疫疾患の治療方法及びそれに関する試薬
IL166156A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Boroproline compound combination therapy
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
BRPI0507972A (pt) 2004-02-23 2007-07-24 Tufts College composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
US20060063719A1 (en) 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US7399869B2 (en) * 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP1898899A4 (en) * 2005-07-05 2009-07-29 Tufts College INHIBITORS OF THE FIBROBLAST ATTACHMENT PROTEIN ALPHA
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation
CA2633803A1 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof
CA2656393A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
WO2008116053A2 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
CN101772507B (zh) * 2007-08-06 2012-12-12 米伦纽姆医药公司 蛋白酶体抑制剂
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
AU2009221976B2 (en) * 2008-03-03 2014-02-27 Kansas State University Research Foundation Protease assay
JP5801585B2 (ja) 2011-03-30 2015-10-28 株式会社ケーヒン 燃料噴射制御システム
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089312A1 (en) * 2002-04-30 2006-04-27 Bachovchin William W Protease inhibitors
WO2008116054A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2009006473A2 (en) * 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILO, L. J. et al., 'Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors', Journal of Medicinal Chemistry. 2011, vol. 54, no. 13, pages 4365-4377. *

Also Published As

Publication number Publication date
PL2753334T3 (pl) 2022-12-12
AU2012301810A1 (en) 2014-04-10
US11065339B2 (en) 2021-07-20
EP4144354B1 (en) 2025-11-26
WO2013033396A2 (en) 2013-03-07
WO2013033396A3 (en) 2014-05-08
HRP20221320T1 (hr) 2023-01-06
CA2846852A1 (en) 2013-03-07
US20160346401A1 (en) 2016-12-01
CN103945856A (zh) 2014-07-23
EP2753334B1 (en) 2022-10-19
US20140255300A1 (en) 2014-09-11
DK2753334T3 (da) 2022-11-07
PT2753334T (pt) 2022-11-03
JP2014527070A (ja) 2014-10-09
US20190054181A1 (en) 2019-02-21
CA2846852C (en) 2021-01-12
HUE060305T2 (hu) 2023-02-28
JP2018016629A (ja) 2018-02-01
US20250367304A1 (en) 2025-12-04
AU2017204121A1 (en) 2017-07-06
EP4144354A1 (en) 2023-03-08
US9956297B2 (en) 2018-05-01
US20200323994A1 (en) 2020-10-15
US9597410B2 (en) 2017-03-21
US10517955B2 (en) 2019-12-31
SI2753334T1 (sl) 2023-01-31
EP2753334A4 (en) 2015-07-01
CN108383893A (zh) 2018-08-10
US12214047B2 (en) 2025-02-04
EP2753334A2 (en) 2014-07-16
ES2929179T3 (es) 2022-11-25
US20210379190A1 (en) 2021-12-09
JP6207509B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
US20250367304A1 (en) Fap-activated proteasome inhibitors for treating solid tumors
KR101823526B1 (ko) 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도
Brady et al. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity
AU2018368520B2 (en) Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B
KR102436012B1 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
CA2411660C (en) Enzyme-cleavable prodrug compounds
HK40089599A (en) Fap-activated proteasome inhibitors for treating solid tumors
JP2001514659A (ja) ドラスタチン−１５誘導体とタキサンとの併用
Pathuri et al. Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor
JP5734209B2 (ja) プロドラッグ
Tripodi Development of a novel class of cyclic NGR peptides for targeted drug delivery
WO2025193583A1 (en) Macrocyclic peptides useful as immunomodulators
WO2025193574A1 (en) Macrocyclic peptides useful as immunomodulators
EA046139B1 (ru) Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b
Tai Development of drug conjugates for cancer therapy and evaluation of dual sirna silencing effect on breast cancer growth and invasion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)